Neuropsychiatric disturbances in atypical parkinsonian disorders. [PDF]
Neuropsychiatr Dis Treat, 2018 Daniele Belvisi,1 Isabella Berardelli,2 Antonio Suppa,1,3 Andrea Fabbrini,3 Massimo Pasquini,3 Maurizio Pompili,2 Giovanni Fabbrini1,3 1IRCCS Neuromed, Pozzilli, Italy; 2Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention ...
Belvisi D +6 more
europepmc +9 more sources
Assisted Suicide in Parkinsonian Disorders. [PDF]
Front Neurol, 2021 Background: Due to the high prevalence of suicidal ideation in Parkinson's Disease (PD) and exploratory data indicating a similar prevalence in atypical Parkinsonian disorders (APD), we sought to determine the frequency of assisted suicide (AS) as well ...
Nuebling GS, Butzhammer E, Lorenzl S.
europepmc +6 more sources
Cerebrospinal fluid biomarker candidates for parkinsonian disorders [PDF]
Frontiers in Neurology, 2013 The parkinsonian disorders are a large group of neurodegenerative diseases including idiopathic Parkinson's disease (PD) and atypical parkinsonian disorders, such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and ...
Radu eConstantinescu, Stefania eMondello
doaj +6 more sources
Pseudobulbar Affect in Parkinsonian Disorders: A Review. [PDF]
J Mov Disord, 2019 Pseudobulbar affect (PBA) is a neurological symptom of inappropriate and uncontrollable laughter or crying that occurs secondary to a variety of neurological conditions, including parkinsonian disorders.
Hakimi M, Maurer CW.
europepmc +4 more sources
Assessing bradykinesia in Parkinsonian disorders [PDF]
Frontiers in Neurology, 2013 Objective: Bradykinesia is one of the clinical hallmarks of Parkinson’s disease (PD) and atypical Parkinsonian syndromes. Clinical ratings scales and technology based assessments have been developed to measure bradykinesia.
Gian ePal, Christopher G Goetz
doaj +3 more sources
Low dose Amantadine and Escitalopram combination in Atypical Parkinsonian disorders- A Retrospective chart review [PDF]
Eur Psychiatry, 2023 Introduction The response to conventional antiparkinsonian medications is elusive in atypical parkinsonian disorders. Improvement in parkinsonian symptoms in atypical parkinsonian disorders has been reported with anecdotal use of Amantadine. The role of
Tripathi S, Chutia P.
europepmc +2 more sources
Molecular Imaging in Parkinsonian Disorders-What's New and Hot? [PDF]
Brain Sci, 2022 Neurodegenerative parkinsonian disorders are characterized by a great diversity of clinical symptoms and underlying neuropathology, yet differential diagnosis during lifetime remains probabilistic.
Prange S +3 more
europepmc +2 more sources
Autonomic Dysfunctions in Parkinsonian Disorders [PDF]
Journal of Movement Disorders, 2009 Background and Purpose: Symptoms of autonomic dysfunctions are common in the patients with parkinsonian disorders. Because clinical features of autonomic dysfunctions are diverse, the comprehensive evaluation is essential for the appropriate management ...
Hyo-Jin Bae +2 more
doaj +3 more sources
Co-occurrence of Convergence Insufficiency and Cognitive Impairment in Parkinsonian Disorders: A Pilot Study. [PDF]
Front Neurol, 2019 Background: Convergence insufficiency (CI) in parkinsonian conditions causes disabling visual symptoms during near tasks and usually manifests as double vision.
Holden SK, Van Dok E, Pelak VS.
europepmc +2 more sources
Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders. [PDF]
J Parkinsons Dis, 2022 Background: Parkinson’s disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) present with similar movement disorder symptoms but distinct protein aggregates upon pathological examination.
Zhu S +3 more
europepmc +2 more sources